MENU
+Compare
NBY
Stock ticker: ASE
AS OF
Apr 24, 10:30 AM (EDT)
Price
$0.58
Change
-$0.00 (-0.00%)
Capitalization
3.4M

NBY NovaBay Pharmaceuticals Forecast, Technical & Fundamental Analysis

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products... Show more

Industry: #Biotechnology
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for NBY with price predictions
Apr 23, 2025

NBY's RSI Indicator recovers from oversold territory

The RSI Oscillator for NBY moved out of oversold territory on April 11, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In of the 41 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 15, 2025. You may want to consider a long position or call options on NBY as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NBY just turned positive on April 15, 2025. Looking at past instances where NBY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBY advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .

NBY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NBY entered a downward trend on April 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.820) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.203) is also within normal values, averaging (252.992).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2000 Powell Street
Phone
+1 510 899-8800
Employees
26
Web
https://www.novabay.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BW0.320.04
+13.70%
Babcock & Wilcox Enterprises
ENVB1.280.05
+4.07%
Enveric Biosciences Inc
NNOX5.110.13
+2.51%
NANO-X IMAGING Ltd
ACAD14.620.27
+1.88%
ACADIA Pharmaceuticals
FMS23.64-0.35
-1.46%
Fresenius Medical Care AG

NBY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been loosely correlated with PRTG. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NBY jumps, then PRTG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
-1.27%
PRTG - NBY
38%
Loosely correlated
-8.72%
ALT - NBY
30%
Poorly correlated
+2.47%
ORMP - NBY
29%
Poorly correlated
+0.66%
DARE - NBY
25%
Poorly correlated
+1.35%
IMMP - NBY
25%
Poorly correlated
+5.88%
More